Does semaglutide protect your heart even if you don't have diabetes?
Yes, and the evidence is strong. The SELECT trial, which enrolled over 17,600 people with pre-existing cardiovascular disease and overweight or obesity (but no diabetes), found that weekly semaglutide (2.4 mg) reduced the combined risk of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke by 20% compared to placebo over nearly 3.5 years [2]. This means that for every 100 people treated, about 1.5 fewer experienced a major heart event. Importantly, this benefit was seen on top of standard heart medications, and the trial was designed to isolate the drug's effect beyond weight loss.
Semaglutide also improves several heart-related risk factors. A meta-analysis of seven trials found that semaglutide lowered systolic blood pressure by an average of 4.2 mmHg and reduced waist circumference by 7.4 cm compared to placebo [3]. In the STEP trials, improvements in blood pressure, triglycerides, and cholesterol were consistently seen with semaglutide [5][6]. These changes are clinically meaningful—a 4 mmHg drop in systolic blood pressure, for example, can reduce stroke risk by about 10-15%.
Can semaglutide help people with heart failure and obesity feel better and move more?
Yes, dramatically. The STEP-HFpEF trial specifically studied 529 patients with heart failure with preserved ejection fraction (a common type of heart failure in people with obesity) and a BMI of 30 or higher. After one year, those on semaglutide (2.4 mg weekly) improved their heart failure symptoms and physical limitations by 16.6 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS), compared to 8.7 points with placebo—a difference of nearly 8 points, which is considered a large and meaningful improvement [4]. They also walked 21.5 meters farther in six minutes, versus only 1.2 meters with placebo [4]. This means people could walk an extra 70 feet—enough to make daily tasks like shopping or climbing stairs noticeably easier.
The same trial also showed that semaglutide reduced inflammation, measured by C-reactive protein (CRP), by 43.5% compared to 7.3% with placebo [4]. Serious adverse events were half as common in the semaglutide group (13.3% vs. 26.7%), suggesting the drug's benefits extend to overall safety in this vulnerable population [4].
Does semaglutide improve quality of life, and do the benefits last?
Yes, semaglutide improves physical functioning and quality of life, and the benefits are maintained as long as the drug is continued. In the STEP 4 trial, people who continued semaglutide for 48 weeks after an initial 20-week run-in lost an additional 7.9% of their body weight, while those switched to placebo regained 6.9% [1]. This shows that stopping the drug leads to rapid weight regain and loss of health benefits. The same trial found that continued semaglutide improved physical functioning scores on the SF-36 survey by 2.5 points more than placebo [1]. A meta-analysis confirmed that semaglutide significantly improves both general physical functioning (SF-36) and obesity-specific quality of life (IWQOL-Lite-CT) scores [3].
However, real-world data show that many patients do not reach the full maintenance dose (2.4 mg weekly) due to the complex titration schedule—only 40% ever receive a claim for the top dose [7]. This is important because the largest health benefits are seen at the highest dose. Additionally, when semaglutide is stopped, most people regain about two-thirds of the lost weight within a year [8], and the cardiometabolic improvements reverse. So, for lasting health benefits beyond weight loss, semaglutide needs to be taken long-term at an adequate dose.
About These Sources
This answer is built on 8 peer-reviewed studies — published from 2021 to 2026, 2 from 2024 or later, 8 in Q1 journals, collectively cited 8,528 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 39 papers retrieved from a database of over 500 million.
Sources used in this answer
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
In a randomized withdrawal trial (STEP 4), continuing semaglutide for 48 weeks after a 20-week run-in led to an additional 7.9% weight loss, while switching to placebo led to 6.9% regain; continued semaglutide also improved waist circumference, blood pressure, and physical functioning scores [1].
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
In the SELECT trial (over 17,600 participants with cardiovascular disease and overweight/obesity but no diabetes), semaglutide reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 20% compared to placebo over a mean follow-up of 39.8 months [2].
Once‐weekly semaglutide for obesity or overweight: A systematic review and meta‐analysis
A meta-analysis of seven randomized controlled trials found that semaglutide significantly reduced body weight (by about 10.6%), waist circumference (by 7.4 cm), and systolic blood pressure (by 4.2 mmHg), and improved physical functioning and quality-of-life scores compared to placebo [3].
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
In the STEP-HFpEF trial (529 patients with heart failure with preserved ejection fraction and obesity), semaglutide improved heart failure symptoms (KCCQ-CSS) by 16.6 points vs. 8.7 with placebo, increased 6-minute walk distance by 21.5 m vs. 1.2 m, and reduced C-reactive protein by 43.5% vs. 7.3% [4].
Semaglutide for the treatment of overweight and obesity: A review
A review of the STEP program reported that semaglutide 2.4 mg produced mean weight losses of 14.9%-17.4% over 68 weeks in people without diabetes, with improvements in blood pressure, lipids, physical function, and quality of life [6].
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In the STEP 1 trial (1,961 adults with overweight/obesity without diabetes), semaglutide 2.4 mg led to a mean weight loss of 14.9% vs. 2.4% with placebo at 68 weeks, with greater improvements in cardiometabolic risk factors and physical functioning [7].
758-P: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset
A real-world claims analysis of 655,419 patients initiating semaglutide for weight loss found that only 40% ever received a claim for the top maintenance dose (2.4 mg), suggesting titration challenges limit real-world effectiveness [9].
Weight maintenance after discontinuation of GLP-1 therapies.
A review of GLP-1 therapy discontinuation found that most patients regain about two-thirds of lost weight within a year of stopping, and cardiometabolic improvements reverse, indicating the need for long-term treatment [10].